-
HORIZON PHARMA, INC. et al v. MYLAN PHARMACEUTICALS et al DC CAFC
- 2:13-cv-04022
- D.N.J.
- Judge: Stanley R. Chesler +1
- Filed: 06/28/2013
- Closed: 07/21/2017
- Latest Docket Entry: 10/03/2019
- PACER
- Docket updated daily
5
Plaintiffs
3
Defendants
2
Accused
Products
8
Patents-in-Suit
1,485
Days in
Litigation
-
HORIZON PHARMA, INC. et al v. MYLAN PHARMACEUTICALS et al DC CAFC
- 2:13-cv-04022
- D.N.J.
- Judge: Stanley R. Chesler +1
- Filed: 06/28/2013
- Closed: 07/21/2017
- Latest Docket Entry: 10/03/2019
- PACER
- Docket updated daily
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
5 |
The pharmaceutical composition of claim 1, wherein said acid inhibitor is a proton pump inhibitor selected from the group consisting of: omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole.
|
Valid
Entry 87 |
15 |
The pharmaceutical composition of any one of claims 1 or 7-14, wherein said acid inhibitor is a proton pump inhibitor.
|
Valid
Entry 87 |
52 |
The method of claim 51, wherein said pain or inflammation is due to either osteoarthritis or rheumatoid arthritis.
|
Valid
Entry 87 |
53 |
The pharmaceutical composition of any one of claims 5-11 wherein said unit dosage form is a multilayer tablet comprising a single core and one or more layers outside of said single core, wherein: i) said NSAID is present in said core; ii) said
view more
|
Valid
Entry 87 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A pharmaceutical composition in unit dosage form comprising therapeutically effective amounts of: (a) esomeprazole, wherein at least a portion of said esomeprazole is not surrounded by an enteric coating; and (b) naproxen surrounded by a coating that
view more
|
Valid
Entry 87 |
2 |
The pharmaceutical composition of claim 1, wherein naproxen is present in said unit dosage form in an amount of 200-600 mg.
|
Valid
Entry 87 |
3 |
The pharmaceutical composition of claim 1, wherein esomeprazole is present in said unit dosage form in an amount of from 5 to 100 mg.
|
Valid
Entry 87 |
4 |
The pharmaceutical composition of claim 1, wherein naproxen is present in said unit dosage form in an amount of between 200-600 mg and esomeprazole in an amount of from 5 to 100 mg per unit dosage form.
|
Valid
Entry 87 |
-
Infringement
Mylan Incorporated
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
375 mg/20 mg , 500 mg/20 mg naproxen/esomeprazole magnesium delayed release tabletsGeneric naproxen/esomeprazole magnesium delayed-release tablets, 375 mg/20 mgGeneric naproxen/esomeprazole magnesium delayed-release tablets, 500 mg/20 mg | US 6,926,907 B2 |
5, 15, 52, 53
|
Infringement
Entry 87
|
375 mg/20 mg , 500 mg/20 mg naproxen/esomeprazole magnesium delayed release tabletsGeneric naproxen/esomeprazole magnesium delayed-release tablets, 375 mg/20 mgGeneric naproxen/esomeprazole magnesium delayed-release tablets, 500 mg/20 mg | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
Entry 87
|
Mylan Laboratories Limited
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
375 mg/20 mg , 500 mg/20 mg naproxen/esomeprazole magnesium delayed release tabletsGeneric naproxen/esomeprazole magnesium delayed-release tablets, 375 mg/20 mgGeneric naproxen/esomeprazole magnesium delayed-release tablets, 500 mg/20 mg | US 6,926,907 B2 |
5, 15, 52, 53
|
Infringement
Entry 87
|
375 mg/20 mg , 500 mg/20 mg naproxen/esomeprazole magnesium delayed release tabletsGeneric naproxen/esomeprazole magnesium delayed-release tablets, 375 mg/20 mgGeneric naproxen/esomeprazole magnesium delayed-release tablets, 500 mg/20 mg | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
Entry 87
|
Mylan Pharmaceuticals
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
375 mg/20 mg , 500 mg/20 mg naproxen/esomeprazole magnesium delayed release tabletsGeneric naproxen/esomeprazole magnesium delayed-release tablets, 375 mg/20 mgGeneric naproxen/esomeprazole magnesium delayed-release tablets, 500 mg/20 mg | US 6,926,907 B2 |
5, 15, 52, 53
|
Infringement
Entry 87
|
375 mg/20 mg , 500 mg/20 mg naproxen/esomeprazole magnesium delayed release tabletsGeneric naproxen/esomeprazole magnesium delayed-release tablets, 375 mg/20 mgGeneric naproxen/esomeprazole magnesium delayed-release tablets, 500 mg/20 mg | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
Entry 87
|